Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs

Clozapine for the Treatment-Resistant Schizophrenic

1988 • 4,030 citations

Glutamate uptake

2001 • 3,867 citations

Implications of Normal Brain Development for the Pathogenesis of Schizophrenia

1987 • 3,683 citations

Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans

1994 • 3,182 citations

Recent advances in the phencyclidine model of schizophrenia

1991 • 2,886 citations

Effect of COMT Val ^108/158 Met genotype on frontal lobe function and risk for schizophrenia

2001 • 2,408 citations

Antipsychotic-Induced Weight Gain: A Comprehensive Research Synthesis

1999 • 2,382 citations

Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs

1976 • 2,224 citations

Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine

1991 • 2,008 citations

Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex

1997 • 1,743 citations

Glutamate Receptor Dysfunction and Schizophrenia

1995 • 1,682 citations

Antipsychotic drug doses and neuroleptic/dopamine receptors

1976 • 1,623 citations

Modulation of memory fields by dopamine Dl receptors in prefrontal cortex

1995 • 1,600 citations

Discovering the Neural Basis of Human Social Anxiety: A Diagnostic and Therapeutic Imperative

2004 • 1,429 citations

Positron Emission Tomographic Analysis of Central D1 and D2 Dopamine Receptor Occupancy in Patients Treated With Classical Neuroleptics and Clozapine

1992 • 1,420 citations

Practice guideline for the treatment of patients with schizophrenia. American Psychiatric Association

1997 • 1,357 citations

Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values.

1989 • 1,313 citations

Risperidone in the treatment of schizophrenia

1994 • 1,205 citations

CANNABIS AND SCHIZOPHRENIA A Longitudinal Study of Swedish Conscripts

1987 • 1,117 citations

Does Fast Dissociation From the Dopamine D₂ Receptor Explain the Action of Atypical Antipsychotics?: A New Hypothesis

2001 • 1,113 citations

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

2000 • 1,079 citations

Relationship Between Dopamine D₂ Occupancy, Clinical Response, and Side Effects: A Double-Blind PET Study of First-Episode Schizophrenia

2000 • 1,036 citations

Antischizophrenic Drugs: Chronic Treatment Elevates Dopamine Receptor Binding in Brain

1977 • 1,017 citations

The Effects of Clozapine, Risperidone, and Olanzapine on Cognitive Function in Schizophrenia

1999 • 1,012 citations

A Meta-analysis of the Efficacy of Second-Generation Antipsychotics

2003 • 1,008 citations

Reversal of Phencyclidine Effects by a Group II Metabotropic Glutamate Receptor Agonist in Rats

1998 • 1,002 citations

Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology

2003 • 918 citations

The Emerging Role of Glutamate in the Pathophysiology and Treatment of Schizophrenia

2001 • 915 citations

Aripiprazole, a Novel Antipsychotic, Is a High-Affinity Partial Agonist at Human Dopamine D2 Receptors

2002 • 896 citations

Atypical Antipsychotics: Mechanism of Action

2002 • 892 citations

Molecular Characterization of Schizophrenia Viewed by Microarray Analysis of Gene Expression in Prefrontal Cortex

2000 • 884 citations

Dopamine receptors and the dopamine hypothesis of schizophrenia

1987 • 867 citations

Catechol- O -methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior

1998 • 859 citations

A subtype of nicotinic cholinergic receptor in rat brain is composed of alpha 4 and beta 2 subunits and is up-regulated by chronic nicotine treatment.

1992 • 858 citations

Catching Up on Schizophrenia

2000 • 815 citations

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials

1999 • 807 citations

D1 receptors in prefrontal cells and circuits

2000 • 804 citations

Prefrontal neurons and the genetics of schizophrenia

2001 • 738 citations

Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET

1997 • 707 citations

Clinical and Theoretical Implications of 5-HT₂ and D₂ Receptor Occupancy of Clozapine, Risperidone, and Olanzapine in Schizophrenia

1999 • 706 citations

The Effects of Risperidone on the Five Dimensions of Schizophrenia Derived by Factor Analysis

1997 • 705 citations

The Effects of Atypical Antipsychotic Drugs on Neurocognitive Impairment in Schizophrenia: A Review and Meta-analysis

1999 • 698 citations

Schizophrenia, Sensory Gating, and Nicotinic Receptors

1998 • 697 citations

Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons

1983 • 680 citations

D-Alanine Added to Antipsychotics for the Treatment of Schizophrenia

2005 • 670 citations

NMDA Receptor Function and Human Cognition: The Effects of Ketamine in Healthy Volunteers

1996 • 667 citations

The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Project: Schizophrenia Trial Design and Protocol Development

2003 • 634 citations

Dopamine D4 receptors elevated in schizophrenia

1993 • 632 citations

Effectiveness of Second-Generation Antipsychotics in Patients With Treatment-Resistant Schizophrenia: A Review and Meta-Analysis of Randomized Trials

2001 • 631 citations

Effects of Xanomeline, a Selective Muscarinic Receptor Agonist, on Cognitive Function and Behavioral Symptoms in Alzheimer Disease

1997 • 625 citations

Efficacy and Safety of Aripiprazole and Haloperidol Versus Placebo in Patients With Schizophrenia and Schizoaffective Disorder

2002 • 624 citations

Studies of Cognitive Change in Patients With Schizophrenia Following Novel Antipsychotic Treatment

2001 • 622 citations

Aripiprazole, an Antipsychotic With a Novel Mechanism of Action, and Risperidone vs Placebo in Patients With Schizophrenia and Schizoaffective Disorder

2003 • 591 citations

Executive Subprocesses in Working Memory

2003 • 591 citations

Differential Effects of Classical and Atypical Antipsychotic Drugs on A9 and A10 Dopamine Neurons

1983 • 589 citations

Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys

1994 • 574 citations

The Glutamatergic Dysfunction Hypothesis for Schizophrenia

1996 • 558 citations

Longitudinal study of brain morphology in first episode schizophrenia

2001 • 558 citations

D-serine added to antipsychotics for the treatment of schizophrenia

1998 • 557 citations

Acute and chronic haloperidol treatment: Comparison of effects on nigral dopaminergic cell activity

1978 • 550 citations

α ₂ -Adrenergic Mechanisms in Prefrontal Cortex Associated with Cognitive Decline in Aged Nonhuman Primates

1985 • 544 citations

Neurocognitive Effects of Clozapine, Olanzapine, Risperidone, and Haloperidol in Patients With Chronic Schizophrenia or Schizoaffective Disorder

2002 • 536 citations

Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: A double-blind PET study of schizophrenic patients

1993 • 529 citations

Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo

2000 • 524 citations

Serotonin model of schizophrenia: emerging role of glutamate mechanisms

2000 • 520 citations

The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor

2002 • 506 citations

5‐HT_2A and D₂ receptor blockade increases cortical DA release via 5‐HT_1A receptor activation: a possible mechanism of atypical antipsychotic‐induced cortical dopamine release

2001 • 491 citations

Quetiapine in Patients With Schizophrenia

1997 • 487 citations

Efficacy of High-Dose Glycine in the Treatment of Enduring Negative Symptoms of Schizophrenia

1999 • 484 citations

Neuropsychological Change in Early Phase Schizophrenia During 12 Months of Treatment With Olanzapine, Risperidone, or Haloperidol

2000 • 478 citations

Is schizophrenia a neurodegenerative disorder? a clinical and neurobiological perspective

1999 • 476 citations

Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials

2003 • 472 citations

The Contribution of α2-Noradrenergic Mechanisms to Prefrontal Cortical Cognitive Function

1996 • 466 citations

Amisulpride, an Unusual “Atypical” Antipsychotic: A Meta-Analysis of Randomized Controlled Trials

2002 • 464 citations

Memory-enhancing effects in male mice of pregnenolone and steroids metabolically derived from it.

1992 • 442 citations

Synaptotagmins: C2-Domain Proteins That Regulate Membrane Traffic

1996 • 439 citations

A Placebo-Controlled Trial of D-Cycloserine Added to Conventional Neuroleptics in Patients With Schizophrenia

1999 • 435 citations

Elevated endogenous cannabinoids in schizophrenia

1999 • 432 citations

Chromogranin A, an “On/Off” Switch Controlling Dense-Core Secretory Granule Biogenesis

2001 • 412 citations

Atypical antipsychotics and weightgain — a systematic review

2000 • 410 citations

Clozapine, Olanzapine, Risperidone, and Haloperidol in the Treatment of Patients With Chronic Schizophrenia and Schizoaffective Disorder

2002 • 410 citations

Modulation of N -methyl- <scp>d</scp> -aspartate receptor function by glycine transport

1998 • 410 citations

Interactions of the Novel Antipsychotic Aripiprazole (OPC-14597) with Dopamine and Serotonin Receptor Subtypes

1999 • 407 citations

Does risperidone improve verbal working memory in treatment-resistant schizophrenia?

1997 • 406 citations

Reversal of Antipsychotic-Induced Working Memory Deficits by Short-Term Dopamine D1 Receptor Stimulation

2000 • 402 citations

A Positron Emission Tomography Study of Quetiapine in Schizophrenia: A Preliminary Finding of an Antipsychotic Effect With Only Transiently High Dopamine D2 Receptor Occupancy

2000 • 401 citations

The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: evidence for alpha-2 receptor subtypes

1988 • 386 citations

Progressive Decrease of Left Superior Temporal Gyrus Gray Matter Volume in Patients With First-Episode Schizophrenia

2002 • 368 citations

5-HT₂ and D₂ Receptor Occupancy of Olanzapine in Schizophrenia: A PET Investigation

1998 • 364 citations

Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity.

1997 • 358 citations

Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia.

1989 • 357 citations

Progressive Decrease of Left Heschl Gyrus and Planum Temporale Gray Matter Volume in First-Episode Schizophrenia

2003 • 356 citations

Binding of 3H-neuroleptics and 3H-apomorphine in schizophrenic brains

1978 • 351 citations

Amelioration of negative symptoms in schizophrenia by glycine

1994 • 349 citations

D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients

1995 • 341 citations

Management of treatment resistance in schizophrenia

2001 • 337 citations

Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response.

1994 • 334 citations

Immunohistochemical localization of PDE10A in the rat brain

2003 • 333 citations

Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer’s disease

2001 • 331 citations

Dehydroepiandrosterone: A potential signalling molecule for neocortical organization during development

1998 • 327 citations

Free d-aspartate and d-serine in the mammalian brain and periphery

1997 • 322 citations

Expert Consensus Guideline Series Treatment of Schizophrenia 1999

1999 • 322 citations

The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary

2003 • 321 citations

The Glycine Site on the NMDA Receptor: Structure-Activity Relationships and Therapeutic Potential

1994 • 320 citations

Control of Serotonergic Function in Medial Prefrontal Cortex by Serotonin-2A Receptors through a Glutamate-Dependent Mechanism

2001 • 317 citations

Introduction: Methods, Commentary, and Summary

2004 • 316 citations

Antipsychotic Drugs

2005 • 315 citations

Overlap of dopaminergic, adrenergic, and serotoninergic receptors and complementarity of their subtypes in primate prefrontal cortex

1990 • 314 citations

Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia

2003 • 310 citations

Receptor pharmacology of neuroleptics: relation to clinical effects.

1999 • 309 citations

Aripiprazole for the Prevention of Relapse in Stabilized Patients With Chronic Schizophrenia

2003 • 308 citations

Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine

1997 • 302 citations

Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer’s disease

2001 • 299 citations

Dopamine D2 and D3 Receptor Occupancy in Normal Humans Treated with the Antipsychotic Drug Aripiprazole (OPC 14597) A Study Using Positron Emission Tomography and [11C]Raclopride

2002 • 299 citations

Potentiation of neuronal NMDA response induced by dehydroepiandrosterone and its suppression by progesterone: effects mediated via sigma receptors

1996 • 296 citations

Antipsychotic drugs which elicit little or no Parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors

1998 • 293 citations

Dose-dependent effects of the dopamine D1 receptor agonists A77636 or SKF81297 on spatial working memory in aged monkeys.

1997 • 292 citations

Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors.

2000 • 290 citations

Increased dopamine D 2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study

2000 • 289 citations

Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol

1997 • 287 citations

Important Issues in the Drug Treatment of Schizophrenia

1980 • 286 citations

Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs

1997 • 284 citations

Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action.

2000 • 282 citations

N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl- <scp>d</scp> -aspartate receptor activity

2003 • 282 citations

Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial

1998 • 273 citations

Neurotensin: perchance an endogenous neuroleptic?

1980 • 272 citations

Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia.

1989 • 271 citations

Schizophrenia

1996 • 270 citations

A “Glutamatergic Hypothesis” of Schizophrenia

1989 • 270 citations

7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity.

1995 • 268 citations

Dehydroepiandrosterone (DHEA) protects hippocampal cells from oxidative stress-induced damage

1999 • 262 citations

Dehydroepiandrosterone sulfate improves memory in aging mice

1988 • 262 citations

Endocannabinoid signalling in the blood of patients with schizophrenia.

2003 • 261 citations

Neuropsychopharmacology: The Fifth Generation of Progress

2003 • 260 citations

High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study

1996 • 257 citations

Double-Blind, Placebo-Controlled, Crossover Trial of Glycine Adjuvant Therapy for Treatment-Resistant Schizophrenia

1996 • 253 citations

Intracellular neuronal calcium sensor proteins: a family of EF-hand calcium-binding proteins in search of a function

1999 • 253 citations

Atypical, but Not Typical, Antipsychotic Drugs Increase Cortical Acetylcholine Release without an Effect in the Nucleus Accumbens or Striatum

2002 • 249 citations

Antipsychotic agents antagonize non-competitiveN-methyl-d-aspartate antagonist-induced behaviors

1995 • 248 citations

Rapid Release of Antipsychotic Drugs From Dopamine D₂ Receptors: An Explanation for Low Receptor Occupancy and Early Clinical Relapse Upon Withdrawal of Clozapine or Quetiapine

1999 • 241 citations

Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia

1995 • 238 citations

Mesolimbic Dopamine D3 Receptors and Use of Antipsychotics in Patients With Schizophrenia

1997 • 236 citations

Dehydroepiandrosterone and its sulfate enhance memory retention in mice

1988 • 232 citations

Glial transporters for glutamate, glycine and GABA I. Glutamate transporters

2001 • 227 citations

Towards a Cannabinoid Hypothesis of Schizophrenia: Cognitive Impairments Due to Dysregulation of the Endogenous Cannabinoid System

1997 • 227 citations

Glycine Uptake Governs Glycine Site Occupancy at NMDA Receptors of Excitatory Synapses

1998 • 219 citations

Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity.

1997 • 215 citations

Atypical Antipsychotics Part I: Pharmacology, Pharmacokinetics, and Efficacy

1999 • 210 citations

Factors influencing relapse in the long-term course of schizophrenia

1997 • 210 citations

The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone

2002 • 209 citations

Serotonergic basis of antipsychotic drug effects in schizophrenia

1998 • 206 citations

Dehydroepiandrosterone Augmentation in the Management of Negative, Depressive, and Anxiety Symptoms in Schizophrenia

2003 • 204 citations

Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of freely-moving rats reveals a complex pattern of reciprocal auto- and heteroreceptor-mediated control of release

1998 • 202 citations

Effects of dehydroepiandrosterone and its sulfate on brain tissue in culture and on memory in mice

1987 • 199 citations

Role of pregnenolone, dehydroepiandrosterone and their sulfate esters on learning and memory in cognitive aging

2001 • 199 citations

The Effects of a Selective D4 Dopamine Receptor Antagonist (L-745,870) in Acutely Psychotic Inpatients With Schizophrenia

1997 • 195 citations

Possible implications of the dopamine D3 receptor in schizophrenia and in antipsychotic drug actions

2000 • 194 citations

Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine

1995 • 194 citations

Glutathione and Signal Transduction in the Mammalian CNS

1999 • 194 citations

Atypical antipsychotic agents: A critical review

2000 • 193 citations

Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum

1998 • 190 citations

Psychotic Reactions Following Cannabis Use in East Indians

1974 • 190 citations

Striatal Excitatory Amino Acid Transporter Transcript Expression in Schizophrenia, Bipolar Disorder, and Major Depressive Disorder

2002 • 189 citations

An Exploratory Haloperidol-Controlled Dose-Finding Study of Ziprasidone in Hospitalized Patients With Schizophrenia or Schizoaffective Disorder

1998 • 188 citations

Expression of Excitatory Amino Acid Transporter Transcripts in the Thalamus of Subjects With Schizophrenia

2001 • 187 citations

A PET Study of Dopamine D₂and Serotonin 5-HT₂Receptor Occupancy in Patients With Schizophrenia Treated With Therapeutic Doses of Ziprasidone

2004 • 184 citations

D-cycloserine added to clozapine for patients with schizophrenia

1996 • 184 citations

Actions of 5-hydroxytryptamine on neurons of the rat cingulate cortex

1993 • 183 citations

Neuroactive Neurosteroids as Endogenous Effectors for the Sigma1 (.SIGMA.1) Receptor. Pharmacological Evidence and Therapeutic Opportunities.

1999 • 181 citations

A placebo-controlled crossover trial of d-cycloserine added to clozapine in patients with schizophrenia

1999 • 179 citations

Dehydroepiandrosterone and its sulfated derivative reduce neuronal death and enhance astrocytic differentiation in brain cell cultures

1987 • 174 citations

An integrated view of pathophysiological models of schizophrenia

1999 • 173 citations

Cannabis induced dopamine release: an in-vivo SPECT study

2001 • 173 citations

Extrastriatal and striatal D₂ dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia

2001 • 172 citations

Extrapyramidal Symptoms and Tolerability of Olanzapine Versus Haloperidol in the Acute Treatment of Schizophrenia

1997 • 171 citations

Network interactions in schizophrenia — therapeutic implications

2000 • 171 citations

Regulation of cortical and subcortical glutamate receptor subunit expression by antipsychotic drugs

1995 • 171 citations

A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia

2002 • 169 citations

Patient response and resource management: another view of clozapine treatment of schizophrenia

1995 • 166 citations

The safety profile of nefazodone.

1996 • 165 citations

Atypical antipsychotics: are some more atypical than others?

2000 • 159 citations

Clozapine and haloperidol modulate N-methyl-D-aspartate- and non-N-methyl-D-aspartate receptor-mediated neurotransmission in rat prefrontal cortical neurons in vitro.

1997 • 158 citations

Positron Emission Tomography Studies on D2 and 5-HT2 Receptor Binding in Risperidone-Treated Schizophrenic Patients

1995 • 156 citations

Neuroprotection by propargylamines in Parkinson's disease

2002 • 155 citations

Pharmacologic treatment of schizophrenia

1999 • 151 citations

Facilitative Effects of the Ampakine CX516 on Short-Term Memory in Rats: Enhancement of Delayed-Nonmatch-to-Sample Performance

1998 • 150 citations

Xanomeline, an M1/M4 preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice

2000 • 147 citations

A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients

1995 • 146 citations

The role of norepinephrine in the pathophysiology of cognitive disorders: potential applications to the treatment of cognitive dysfunction in schizophrenia and Alzheimer's disease

1999 • 145 citations

Lack of apparent antipsychotic effect of the D1-dopamine recepotr antagonist SCH39166 in acutely ill schizophrenic patients

1995 • 144 citations

Pharmacologic strategies for augmenting cognitive performance in schizophrenia

1999 • 142 citations

Differential behavioural and neurochemical effects of competitive and non-competitive NMDA receptor antagonists in rats

1992 • 140 citations

Dopamine-induced oxidative stress in neurons with glutathione deficit: implication for schizophrenia

2003 • 138 citations

Dr. Meltzer and Mr. Cola Reply

1995 • 137 citations

Idazoxan and Response to Typical Neuroleptics in Treatment-Resistant Schizophrenia

1996 • 134 citations

Quality of life as a predictor for change in disability in MS

2000 • 131 citations

Muscarinic Receptors as a Target for Drugs Treating Schizophrenia

2002 • 129 citations

Cognitive Function in Schizophrenia— Do Neuroleptics Make a Difference?

1997 • 128 citations

Effects of Risperidone in Tardive Dyskinesia: An Analysis of the Canadian Multicenter Risperidone Study*

1995 • 127 citations

Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation

1998 • 127 citations

Current and Novel Approaches to the Drug Treatment of Schizophrenia

2001 • 126 citations

The relationship between D 2 receptor occupancy and plasma levels on low dose oral haloperidol: a PET study

1997 • 126 citations

Dehydroepiandrosterone sulfate attenuates dizocilpine-induced learning impairment in mice via σ1-receptors

1997 • 125 citations

Binding of Antipsychotic Drugs to Cortical 5-HT_2A Receptors: A PET Study of Chlorpromazine, Clozapine, and Amisulpride in Schizophrenic Patients

1998 • 125 citations

Neurotensin is an antagonist of the human neurotensin NT2 receptor expressed in Chinese hamster ovary cells

1998 • 124 citations

Schizophrenia and L-745, 870, a novel dopamine D4 receptor antagonist

1997 • 124 citations

Clozapine improves deficient inhibitory auditory processing in DBA/2 mice, via a nicotinic cholinergic mechanism

2003 • 123 citations

S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: II. Functional and behavioral profile compared with GR218,231 and L741,626.

2000 • 120 citations

Facilitative Effects of the Ampakine CX516 on Short-Term Memory in Rats: Correlations with Hippocampal Neuronal Activity

1998 • 116 citations

Potentiation by dehydroepiandrosterone of the neuronal response to N-methyl-D-aspartate in the CA3 region of the rat dorsal hippocampus: an effect mediated via sigma receptors.

1996 • 114 citations

Understanding the Mechanism of Action of Atypical Antipsychotic Drugs

1993 • 110 citations

Clozapine is a partial agonist at cloned, human serotonin 5-HT1A receptors

1996 • 110 citations

Guanfacine Treatment of Cognitive Impairment in Schizophrenia

2001 • 109 citations

Neuroprotection by dehydroepiandrosteronesulfate

1998 • 109 citations

Is Regionally Selective D₂/D₃Dopamine Occupancy Sufficient for Atypical Antipsychotic Effect? An In Vivo Quantitative [¹²³I]Epidepride SPET Study of Amisulpride-Treated Patients

2003 • 108 citations

The current status of neuroleptic therapy.

1989 • 108 citations

Neuropsychologic Deficits in Schizophrenia Relation to Social Function and Effect of Antipsychotic Drug Treatment

1996 • 106 citations

Intragastric DMXB-A, an α7 nicotinic agonist, improves deficient sensory inhibition in DBA/2 mice

2001 • 105 citations

Allosteric Modulation of Nicotinic Receptors as a Treatment Strategy for Alzheimer’s Disease

2000 • 104 citations

8-OH-DPAT, a 5-HT 1A agonist and ritanserin, a 5-HT 2A/C antagonist, reverse haloperidol-induced catalepsy in rats independently of striatal dopamine release

1997 • 103 citations

Neurotrophic factors and the maldevelopmental hypothesis of schizophrenic psychoses

1998 • 102 citations

Cognitive improvement during Tolcapone treatment in Parkinson's disease

1997 • 99 citations

An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia

2002 • 99 citations

Review of atypical antipsychotics and weight gain.

2001 • 99 citations

Dose dependent occupancy of central dopamine D2 receptors by the novel neuroleptic CP-88,059-01: a study using positron emission tomography and11C-raclopride

1993 • 98 citations

In Vivo Extrastriatal and Striatal D2 Dopamine Receptor Blockade by Amisulpride in Schizophrenia

2001 • 93 citations

Understanding antipsychotic "atypicality": a clinical and pharmacological moving target.

2003 • 93 citations

Differential effects of the D1-DA receptor antagonist SCH39166 on positive and negative symptoms of schizophrenia

1995 • 93 citations

D2 and 5-HT2 receptor effects of antipsychotics: bridging basic and clinical findings using PET.

1999 • 92 citations

Comparison of the effects of clozapine, risperidone, and olanzapine on ketamine-induced alterations in regional brain metabolism.

2000 • 92 citations

The effects of neurosteroids on acquisition and retention of a modified passive-avoidance learning task in mice

1998 • 91 citations

Behavioural and neurochemical effects of OPC-14597, a novel antipsychotic drug, on dopaminergic mechanisms in rat brain

1995 • 91 citations

Mechanisms of typical and atypical antipsychotic drug action in relation to dopamine and NMDA receptor hypofunction hypotheses of schizophrenia

1999 • 91 citations

The role of dopamine and AMPA/kainate receptors in the nucleus accumbens in the hypermotility response to MK801

1993 • 90 citations

Placebo-Controlled Study of the D₄/5-HT_2A Antagonist Fananserin in the Treatment of Schizophrenia

1999 • 90 citations

The role of neurotensin in the pathophysiology of schizophrenia and the mechanism of action of antipsychotic drugs

2001 • 88 citations

Selective Antagonism at Dopamine D3 Receptors Enhances Monoaminergic and Cholinergic Neurotransmission in the Rat Anterior Cingulate Cortex

2002 • 88 citations

Direct determination of dopamine D4 receptors in normal and schizophrenic postmortem brain tissue: a [3H]NGD-94-1 study

1998 • 87 citations

Clonidine improves memory function in schizophrenia independently from change in psychosis☆Preliminary findings

1988 • 87 citations

Dopamine receptor subtypes: differential regulation after 8 months treatment with antipsychotic drugs.

1997 • 86 citations

Regulation of ionotropic glutamate receptors following subchronic and chronic treatment with typical and atypical antipsychotics

1996 • 86 citations

Metabotropic Glutamate Receptors: Potential Drug Targets for the Treatment of Schizophrenia

2002 • 85 citations

Pharmacological characterization of U-101387, a dopamine D4 receptor selective antagonist.

1996 • 85 citations

The time course of binding to striatal dopamine D2 receptors by the neuroleptic ziprasidone (CP-88,059-01) determined by positron emission tomography

1996 • 84 citations

Effects of α4/β2- and α7-nicotine acetylcholine receptor agonists on prepulse inhibition of the acoustic startle response in rats and mice

2001 • 84 citations

Selective dopamine D 4 receptor antagonists reverse apomorphine-induced blockade of prepulse inhibition

1998 • 83 citations

Changes in apomorphine-induced stereotypy as a result of subacute neuroleptic treatment correlates with increased D-2 receptors, but not with increases in D-1 receptors

1983 • 82 citations

In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia

1996 • 82 citations

Synergistic interactions between ampakines and antipsychotic drugs.

1999 • 82 citations

Blockade of cannabinoid receptors by SR141716 selectively increases Fos expression in rat mesocorticolimbic areas via reduced dopamine D2 function

1999 • 81 citations

Antipsychotic drug treatment induces differential gene expression in the rat cortex

2002 • 81 citations

Nitric oxide synthase inhibition blocks phencyclidine-induced behavioural effects on prepulse inhibition and locomotor activity in the rat

1997 • 80 citations

Long-Term Effects of Olanzapine, Risperidone, and Quetiapine on Ionotropic Glutamate Receptor Types: Implications for Antipsychotic Drug Treatment

2003 • 79 citations

Novel antipsychotic-like effects on prepulse inhibition of startle produced by a neurotensin agonist.

1999 • 78 citations

Effects of dihydrexidine, a full dopamine D-1 receptor agonist, on delayed response performance in chronic low dose MPTP-treated monkeys

1994 • 77 citations

Quetiapine

2000 • 75 citations

Dopamine D3 Receptor Ligands with Antagonist Properties

2002 • 75 citations

Regulation of NMDA receptor subunit messenger RNA levels in the rat brain following acute and chronic exposure to antipsychotic drugs

1997 • 74 citations

Adjuvant Galantamine Administration Improves Negative Symptoms in a Patient With Treatment-Refractory Schizophrenia

2002 • 74 citations

Nicotinic Agonists and Psychosis

2002 • 74 citations

Pre-clinical Pharmacology of Atypical Antipsychotic Drugs: A Selective Review

1996 • 74 citations

Reversal of Phencyclidine-Induced Hyperactivity by Glycine and the Glycine Uptake Inhibitor Glycyldodecylamide

1997 • 74 citations

The role of dopamine D4 receptor in the induction of behavioral sensitization to amphetamine and accompanying biochemical and molecular adaptations.

1998 • 73 citations

Clozapine, but not haloperidol, prevents the functional hyperactivity of N-methyl-D-aspartate receptors in rat cortical neurons induced by subchronic administration of phencyclidine.

1999 • 73 citations

Translating the basic and clinical cognitive neuroscience of schizophrenia to drug development and clinical trials of antipsychotic medications

2001 • 72 citations

Aripiprazole: A New Atypical Antipsychotic Drug

2003 • 72 citations

Neuroleptic treatment of negative symptoms in schizophrenic patients. Efficacy problems and methodological difficulties

1993 • 71 citations

Modulation of Nicotinic Receptor Activity in the Central Nervous System

2001 • 70 citations

Catechol 0-methyltransferase inhibitor tolcapone has minor influence on performance in experimental memory models in rats

1997 • 70 citations

Glycyldodecylamide, a phencyclidine behavioral antagonist, blocks cortical glycine uptake: implications for schizophrenia and substance abuse

1997 • 70 citations

Broad therapeutic uses of atypical antipsychotic medications

2001 • 70 citations

Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours

2002 • 69 citations

Blockade of cannabinoid (CB1) receptors by SR 141716 selectively antagonizes drug-induced reinstatement of exploratory behaviour in gerbils

1999 • 69 citations

Calcineurin and intracellular Ca2+-release channels: regulation or association?

2003 • 68 citations

Cognitive dysfunction in schizophrenia and its importance to outcome: the place of atypical antipsychotics in treatment.

1999 • 66 citations

The potential of subtype-selective neuronal nicotinic acetylcholine receptor agonists as therapeutic agents

1998 • 66 citations

COMT inhibitors and liver toxicity.

2000 • 66 citations

M100907 and Clozapine, but not Haloperidol or Raclopride, Prevent Phencyclidine-Induced Blockade of NMDA Responses in Pyramidal Neurons of the Rat Medial Prefrontal Cortical Slice

1998 • 66 citations

Negative Symptoms in Schizophrenia: Neurobiological Models and Treatment Response

1998 • 66 citations

Preliminary experience with an ampakine (CX516) as a single agent for the treatment of schizophrenia: a case series

2002 • 66 citations

Decreased gene expression of glial and neuronal glutamate transporters after chronic antipsychotic treatment in rat brain

2003 • 65 citations

7-Nitroindazole and Methylene Blue, Inhibitors of Neuronal Nitric Oxide Synthase and NO-Stimulated Guanylate Cyclase, Block MK-801-Elicited Behaviors in Mice

1996 • 60 citations

Mechanism of Peripheral Noradrenergic Stimulation by Clozapine

1999 • 60 citations

Comparison of the Binding Activities of Some Drugs on α_2A, α_2B and α_2C‐Adrenoceptors and Non‐Adrenergic Imidazoline Sites in the Guinea Pig

1995 • 58 citations

Methylene Blue Adjuvant Therapy of Schizophrenia

1997 • 58 citations

The American Psychiatric Press Textbook of Psychopharmacology

1995 • 57 citations

Effects of Long-Term Antipsychotic Treatment on NMDA Receptor Binding and Gene Expression of Subunits

2003 • 57 citations

Positron emission tomographic analysis of central 5-hydroxytryptamine2 receptor occupancy in healthy volunteers treated with the novel antipsychotic agent, ziprasidone.

1996 • 57 citations

Towards the improvement of compliance

1997 • 57 citations

Hipótese glutamatérgica da esquizofrenia

2003 • 56 citations

Neurosteroids Ameliorate Conditioned Fear Stress An Association with Sigma1 Receptors

2000 • 56 citations

8,9-Dihydroxy-2,3,7,11b-tetrahydro-1H-naph[1,2,3-de]isoquinoline: A Potent Full Dopamine D₁ Agonist Containing a Rigid β-Phenyldopamine Pharmacophore

1996 • 55 citations

Clozapine and haloperidol differentially affect AMPA and kainate receptor subunit mRNA levels in rat cortex and striatum

1997 • 55 citations

SIB-1553A, (+/-)-4-[[2-(1-methyl-2-pyrrolidinyl)ethyl]thio]phenol hydrochloride, a subtype-selective ligand for nicotinic acetylcholine receptors with putative cognitive-enhancing properties: effects on working and reference memory performances in aged rodents and nonhuman primates.

2001 • 55 citations

Effects of σ1 receptor agonist SA4503 and neuroactive steroids on performance in a radial arm maze task in rats

2000 • 54 citations

Novel antipsychotics: issues and controversies. Typicality of atypical antipsychotics.

2000 • 54 citations

The non-NMDA glutamate receptor antagonist GYKI 52466 counteracts locomotor stimulation and anticataleptic activity induced by the NMDA antagonist dizocilpine

1993 • 53 citations

Treatment of Negative Symptoms in Schizophrenia and Schizoaffective Disorder by Selegiline Augmentation of Antipsychotic Medication

1996 • 52 citations

Negative symptoms: diagnosis, treatment and prognosis

1996 • 52 citations

Schizophrenia (2nd edn). Edited by Steven R. Hirsch &amp; Daniel R. Weinberger Oxford: Blackwell. 2003. 768 pp. £89.50 (hb). ISBN 0 632063882

2004 • 52 citations

Neurotensin: an endogenous antipsychotic?

2002 • 51 citations

Modulation of glutamate receptors in response to the novel antipsychotic olanzapine in rats

2001 • 51 citations

Effects of antipsychotic drugs on dopamine and serotonin contents and metabolites, dopamine and serotonin transporters, and serotonin 1A receptors

1999 • 51 citations

Deconstructing Schizophrenia

2003 • 51 citations

Nitric Oxide Synthase Inhibitors Attenuate Phencyclidine-Induced Disruption of Prepulse Inhibition

1998 • 50 citations

Regulation of Ionotropic Glutamate Receptors in the Rat Brain in Response to the Atypical Antipsychotic Seroquel (Quetiapine Fumarate)

1999 • 49 citations

Blunted brain metabolic response to ketamine in mice lacking D1A dopamine receptors

2001 • 49 citations

In vivo occupancy of striatal and temporal cortical D₂/D₃ dopamine receptors by typical antipsychotic drugs

1999 • 49 citations

Differential regulation of hippocampal AMPA and kainate receptor subunit expression by haloperidol and clozapine.

1996 • 48 citations

Schizophrenia and L-745, 870, a novel dopamine D4 receptor antagonist

1997 • 48 citations

Involvement of nitric oxide in phencyclidine-induced hyperlocomotion in mice

1995 • 47 citations

Differential effects of haloperidol and clozapine on ionotropic glutamate receptors in rats

1999 • 47 citations

Striatal Extracellular Dopamine Levels in Rats with Haloperidol-Induced Depolarization Block of Substantia Nigra Dopamine Neurons

1998 • 46 citations

The effects of systemic NT69L, a neurotensin agonist, on baseline and drug-disrupted prepulse inhibition

2003 • 46 citations

Tolcapone-Related Liver Dysfunction

2003 • 44 citations

DNQX inhibits phencyclidine (PCP) and ketamine induction of the hsp70 heat shock gene in the rat cingulate and retrosplenial cortex

1995 • 44 citations

The effect of chronic haloperidol treatment on glutamate receptor subunit (GluR1, GluR2, KA1, KA2, NR1) mRNAs and glutamate binding protein mRNA in rat forebrain

1996 • 43 citations

Biological Perspectives

2002 • 42 citations

Current Issues in the Psychopharmacology of Schizophrenia

2002 • 42 citations

Behavioral Evidence of Depolarization Block of Dopamine Neurons after Chronic Treatment with Haloperidol and Clozapine

2000 • 42 citations

Schizophrenia and mood disorders : the new drug therapies in clinical practice

1999 • 42 citations

Chronic haloperidol and clozapine administration increases the number of cortical NMDA receptors in rats

1999 • 41 citations

Dehydroisoandrosterone in Psychiatric Treatment

1952 • 41 citations

Depolarization inactivation of dopamine neurons: an artifact?

1995 • 41 citations

New drugs for the treatment of schizophrenic patients

1995 • 40 citations

The role of glutamate receptors in antipsychotic drug action

2000 • 39 citations

Further Studies on Endocrine Treatment in Adolescence and Early Adult Life

1954 • 38 citations

Dr. Goff Replies

1995 • 37 citations

Anti-apoptotic function of propargylamine inhibitors of type-B monoamine oxidase

2003 • 36 citations

Donepezil in schizophrenia — is it helpful? An experimental design case study

2001 • 36 citations

Repeated Administration of the Neurotensin Receptor Antagonist SR 48692 Differentially Regulates Mesocortical and Mesolimbic Dopaminergic Systems

1998 • 35 citations

Chronic treatment with haloperidol diminishes the phencyclidine-induced sensorimotor gating deficit in rats

1998 • 34 citations

Clozapine: a comparison with other novel antipsychotics.

1999 • 33 citations

Chronic Administration of Haloperidol and Olanzapine Attenuates Ketamine-Induced Brain Metabolic Activation

2003 • 33 citations

Temporal variations in androgens and stress hormones in control and schizophrenic subjects.

1979 • 33 citations

Blockade of neurokinin3 receptors antagonizes drug-induced population response and depolarization block of midbrain dopamine neurons in guinea pigs

1999 • 31 citations

Long-term effects of neuroleptic drugs on the neuroendocrine system.

1985 • 31 citations

The new and evolving pharmacotherapy of schizophrenia

2003 • 31 citations

Clozapine response varies in deficit vs non-deficit schizophrenic subjects

1994 • 29 citations

Effect of chronic clozapine administration on [3H]MK801-binding sites in the rat brain: a side-preference action in cortical areas

1997 • 28 citations

Antipsychotic drug regulation of AMPA receptor affinity states and GluR1, GluR2 splice variant expression

1998 • 26 citations

Deprenyl Augmentation for Treating Negative Symptoms of Schizophrenia: A Double-Blind, Controlled Study

1999 • 25 citations

Assessing the effects of atypical antipsychotics on negative symptoms

1998 • 25 citations

The Relevance of the Dopamine-D1 Receptor in the Cognitive Symptoms of Schizophrenia

1999 • 24 citations

Developing novel antipsychotic drugs: Strategies and goals

2000 • 23 citations

Failure of chronic haloperidol to induce depolarization inactivation of dopamine neurons in unanesthetized rats

1994 • 23 citations

Effects of modulation of nitric oxide on acoustic startle responding and prepulse inhibition in rats

1997 • 23 citations

Haloperidol does not produce dopamine cell depolarization-block in paralyzed, unanesthetized rats

1998 • 22 citations

Schizophrenia: A genetic perspective (Review)

2002 • 22 citations

Therapeutic efficacy of a partial dopamine agonist in drug-free parkinsonian patients

1985 • 22 citations

New Developments in the pharmacotherapy of schizophrenia

2003 • 21 citations

Atypical antipsychotic-like effects of the dopamine D3 receptor agonist, (+)-PD 128,907

1998 • 21 citations

Further Evidence that Behavioral Tests and Neuropeptide mRNA and Tissue Level Alterations Can Differentiate between Typical and Atypical Antipsychotic Drugs

2000 • 21 citations

Evaluating the effects of antipsychotics on cognition in schizophrenia

1998 • 20 citations

Neuroactive steroids: new biomarkers of cognitive aging

2003 • 20 citations

Donepezil for memory dysfunction in schizophrenia

2002 • 20 citations

Olanzapine, quetiapine, and risperidone: long-term effects on monoamine transporters in rat forebrain

2000 • 20 citations

Chronic treatments with zotepine, thioridazine, and haloperidol affect apomorphine-elicited stereotypic behavior and striatal 3H-spiroperidol binding sites in the rat

1981 • 20 citations

Common treatment goals of antipsychotics: acute treatment.

1998 • 20 citations

Effects of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) after repeated administration on a conditioned avoidance response (CAR) in the rat

1992 • 19 citations

S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: I. Receptorial, neurochemical, and electrophysiological profile.

2000 • 19 citations

USE OF DEHYDROISOANDROSTERONE IN PSYCHIATRIC PRACTICE

1955 • 18 citations

Osanetant Sanofi-Synthélabo.

2001 • 17 citations

PRE- AND POSTSYNAPTIC D1 TO D5 DOPAMINE RECEPTOR MECHANISMS IN RELATION TO ANTIPSYCHOTIC ACTIVITY

1993 • 17 citations

Selegiline augmentation of antipsychotics for the treatment of negative symptoms in schizophrenia

1999 • 17 citations

Pharmacological Manipulation of D1-Dopamine Receptor Function in Schizophrenia

1999 • 16 citations

Advances in the pharmacogenetic prediction of antipsychotic response

2003 • 14 citations

Psychiatry, 2nd Edn

2005 • 13 citations

Atypical antipsychotic-like effect of AMPA receptor antagonists in the rat

2000 • 10 citations

Chronic treatments with haloperidol and clozapine alter the level of NMDA-R1 mRNA in the rat brain: an in situ hybridization study.

2002 • 10 citations

Risperidone versus haloperidol for prevention of relapse in schizophrenia and schizoaffective disorders: Long-term double-blind comparison

2000 • 8 citations

When Neurotrophic Factors Get on Your Nerves: Therapy for Neurodegenerative Disorders

1998 • 7 citations

The neurochemical and behavioral effects of papaverine in vivo suggest PDE10 inhibition is “antipsychotic”

2003 • 6 citations

S.01.01 Antipsychotic effect of four different compounds — results of the metatrial

2003 • 6 citations

Deleted Work

1955 • 0 citations